- 學位論文
蘆筍莖標準化萃取物對早期階段阿茲海默症的熱休克蛋白70表現的影響
Evaluation of the Effect of the Standardized Extract of Asparagus Officinalis Stem on the Expression of Heat Shock Protein 70 on the Early Stage of Alzheimer’s Disease
摘要
背景：許多研究顯示熱休克蛋白70（HSP70）在體內與體外實驗中均可抑制阿茲海默症的進展。因此，專注於HSP70及相關的化合物，或許是個有潛力的阿茲海默症治療策略。 目標：透過雙盲、安慰劑控制的實驗，探討酵素處理的蘆筍萃取物（Enzyme-treated Asparagus Extract，簡稱ETAS）對早期階段的阿茲海默症有何影響。 方法與材料：本研究評估了30位51–79 歲間的輕度認知障礙患者。患者被分為兩組（各為15人），分別服用安慰劑（糊精，第1組）與ETAS（第2組）12個月。為評估患者的神經狀況，在治療前後對患者進行神經心理測驗（簡易智能測驗，Mini-Mental State Examination，簡稱MMSE）、額葉功能測試（Frontal Assessment Battery，簡稱FAB）、畫鐘測驗（Clock Test）、醫院焦慮與憂鬱量表（ Hospital Anxiety and Depression Scale，簡稱HADS）、 HSP70（ELISA試劑盒）血液測試、CD4陽性與／CD8陽性細胞（CD4／CD8）之比例、腦部核磁共振與腦電波圖。 結果：與第1組相比，第2組（服用ETAS）患者的狀態有顯著的改善。第2組中，所有患者在12個月內的認知狀態均發生了正向變化。HSP70及CD4／CD8比例的驗血結果顯示，第2組阿茲海默症輕度障礙患者出現顯著改善（р＜0.05）。在中度障礙方面，兩組有相似的熱休克蛋白（HSP）結果（第1組為50.2％，第2組為61.2％），但免疫調節指（immunoregulatory index，簡稱immunoregulatory index，CD4／CD8）的結果有顯著差異（р＜0.05）：第1組為快速增長（高達34％），第2組則顯著下降（至4.3%）。 結論與建議：蘆筍萃取物能可靠地產生HSP70表現，特別是在早期的阿茲海默症中，從而改善了病患的認知狀態。
並列摘要
Background: Numerous studies based on in vitro and in vivo experiments have indicated that heat shock protein 70 (HSP70) could suppress the progression of Alzheimer’s disease (AD). As such, targeting HSP70 and the related compounds might represent a promising strategy for the treatment of AD. Objective: To investigate the effects of enzyme-treated asparagus extract (ETAS) on the early stage of AD via a double-blind placebo-controlled study. Methods and Materials: A total of 30 patients between 51–79 years old with mild cognitive disorders were assessed. The patients were divided into two groups (n = 15). Group 1 took a placebo (dextrin), while Group 2 took ETAS for 12 months. Neurological status was assessed; neuropsychological testing (Mini-Mental State Examination [MMSE], Frontal Assessment Battery [FAB], Clock Drawing Test [CDT], Hospital Anxiety and Depression Scale [HADS]) was conducted; and HSP70 (ELISA) and CD4/CD8 blood tests, brain magnetic resonance imaging (MRI), and electroencephalogram (EEG) were performed before and after treatment. Results: Patients in Group 2 (those taking ETAS) showed significant improvement compared with Group 1. All patients in Group 2 had positive changes in their cognitive status during the 12-month period. The results of the HSP70 and CD4/CD8 blood tests showed significant improvement for Group 2 patients with mild disorders (р < 0.05). Concerning moderate disorders, heat shock protein (HSP) results were comparable between both groups (50.2% in Group 1 and 61.2% in Group 2), but IRI (immunoregulatory index, CD4/CD8) results differed markedly (р < 0.05), with fast growth (up to 34%) in Group 1 and significantly lowered growth (to 4.3%) in Group 2. Conclusion and Suggestions: ETAS reliably produces HSP70 expression, especially when administered during early stages of Alzheimer's disease, and it improves the cognitive status of patients. The mode of action may be related to the upregulation of HSP70 expression and adjustment to a suitable ratio of CD4/CD8.